Douglas signs new cancer drug R&D deal with Manchester Uni

By Paul McBeth
Feb. 1 (BusinessDesk) - Douglas Pharmaceuticals, the country's biggest drugs developer and manufacturer, has signed a research and licensing deal with the University of Manchester's innovation unit, UMI3, to repurpose an HIV drug to prevent early-stage cervical cancer.
Auckland-based Douglas Pharmaceuticals will sponsor research at Manchester University to build on work, including a phase one trial in Kenya, that's found a drug commonly used to treat HIV was active against human papilloma virus (HPV), which causes almost a...
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out more.
We are serious about journalism.
Already a Subscriber ? Sign in here.
{{ registerForm.errors.get('form') }}
We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.
{{ cardForm.errors.get('card') }}
{{ registerForm.errors.get('plan') }}
{{ __(plans[index].name) | capitalize }}
{{ plans[index].attributes.old_price | currency }}
{{ plans[index].price | currency }}
All subscriptions auto renew but are easy to cancel.
Tax: {{ taxAmount(selectedPlan) | currency }}
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
{{ registerForm.errors.get('email') }}
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.